SITC 2017 Abstract Titles – Various

To search for abstract content based on keywords, select CTRL+F on your keyboard (or Command+F if you're using a Mac) and type a keyword to search for abstracts related to that keyword.







Enhancement of CAR-T Cell Tumor Tropism through Expression of CXCR2 Chemokine Receptors

Ismahene Benzaid1, Daniel Santiago1, Cecilia Ramello1, Mibel Pabon1, Wendy Kandell1, Theresa Boyle1, Anders Berglund1, Scott Antonia1, Daniel Abate-Daga1

1Moffitt Cancer Center, Tampa, Florida, USA

Adoptive immunotherapy | Antigen presenting cells | CAR T cells |Chemokine |Targeted therapy | Solid tumors | T cell


First in human, single ascending dose study in healthy volunteers of SNDX-6352, a humanized IgG4 monoclonal antibody targeting colony stimulating factor-1 receptor (CSF-1R)

Renger Tiessen1, Anniek Visser2, Henko Tadema2, Caryn Peterson3, Helen Pentikis3, Lei Wang3, Michael L. Meyers4, Peter Ordentlich3

1PRA Health Sciences, Groningen, Netherlands 2PRA Bioanalytical Laboratory, Assen, Netherlands 3Syndax Pharmaceuticals, Inc., Waltham, Massachussets, USA 4Syndax Pharmaceuticals, Inc., New York, New York, USA

Clinical study | Antibody | Clinical trial | Cytokine | Monocyte/Macrophage


A Phase 1, First-in-Human, Dose Escalation, Dose Expansion Study of MSC-1, A Humanized anti-LIF Monoclonal Antibody, in Patients with Relapsed/Refractory Metastatic Solid Tumors

David Hyman1, Irene Braña2, Anna Spreafico3, Naimish Pandya4, Kimberly Hoffman4, Robin Hallett4, Patricia Giblin4, Angus Sinclair4, Judit Andito4, Isabel Huber Ruano4, Jeanne Magram4, Robert Wasserman4, Ada Sala, Monica Pascual, Vanessa Chiganças, Joan Seoane

1Memorial Sloan Kettering Cancer Center, New York, New York, USA 2Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain 3Princess Margaret Cancer Center, Toronto, Ontario, Canada 4Northern Biologics, Toronto, Ontario, Canada

Tumor microenvironment | Clinical study | Tumor stroma | Antibody | Clinical trial | Immune suppression | Solid tumors


Cancer Patient Blood Plasmablasts Reveal Functional Antibodies With Anti-Tumor Activity

Gilson Baia1, Amy Manning-Bog1, Alexander Scholz1, Jeff DeFalco1, Michael Harbell1, Danhui Zhang1, Feliz Chu1, Patricia Zuno-Mitchell1, Judevin Lugar Sapugay1, Beatriz Millare1, May Sumi1, Christine Dowd1, Dongkyoon Kim1, Xiaomu Chen1, Sean Carroll1, Gregg Espiritu Santo1, Nicole Haaser1, Ngan Nguyen1, Eldar Giladi1, David Minor1, Yann Chong Tan1, Jeremy Sokolove2, Lawrence Steinman2, Tito A. Serafini1, Guy Cavet1, Norman M. Greenberg1, Jacob Glanville2, Wayne Volkmuth1, Daniel E. Emerling1, William H. Robinson2

1Atreca, Inc, Redwood, CA, USA 2Standford University, Stanford, CA

Tumor microenvironment | Checkpoint blockade| Tumor antigens | Antibody | B cell | Solid tumors | Tumor infiltrating lymphocytes (TILs)